CAJ | 학술논문

目的：观察小剂量尿激酶联合低分子肝素治疗进展性脑梗死的疗效与安全性。方法将62例进展性脑梗死患者随机分为治疗组（32例）与对照组（30例）。对照组采用常规治疗，治疗组在常规治疗基础上，加用尿激酶20万U＋生理盐水250 ml静滴，低分子肝素钠5000U皮下注射，每日1次，连用7d。治疗前、治疗后7d、14d对两组患者的神经功能缺损程度评分（NDS）进行评定。结果治疗组总有效率90.63%优于对照组70.00%；治疗后NDS 7 d、14 d分别为（12.74±6.72）分、（13.85±7.93）分低于对照组的（24.71±8.51）分、（20.75±9.01）分，P＜0.01，差异具有统计学意义；两组均无明显不良反应。结论小剂量尿激酶联合低分子肝素治疗进展性脑梗死安全有效。
목적：관찰소제량뇨격매연합저분자간소치료진전성뇌경사적료효여안전성。방법장62례진전성뇌경사환자수궤분위치료조（32례）여대조조（30례）。대조조채용상규치료，치료조재상규치료기출상，가용뇨격매20만U＋생리염수250 ml정적，저분자간소납5000U피하주사，매일1차，련용7d。치료전、치료후7d、14d대량조환자적신경공능결손정도평분（NDS）진행평정。결과치료조총유효솔90.63%우우대조조70.00%；치료후NDS 7 d、14 d분별위（12.74±6.72）분、（13.85±7.93）분저우대조조적（24.71±8.51）분、（20.75±9.01）분，P＜0.01，차이구유통계학의의；량조균무명현불량반응。결론소제량뇨격매연합저분자간소치료진전성뇌경사안전유효。
Objective To observe the efficacy and safety of low dose of urokinase combined with low molecular weight heparin in treatment of acute and progressive cerebral infarction. Methods Selected 62 cases with acute cerebral infarction were randomly divided into treatment group (n=32) and the control group (n=30). The treatment group was treated with urokinase 20×104 U and low dose urokinase 5 000 U, the control group was treated routinely therapy. Above-mentioned drug were dissolved in sodium chloride 250 ml iv drip once a day for 7 days respectively. The nervous function defect scores were oberserved before therapy and after treatment at 7 day and 14 day. Results The total effective rate of the treatment group 90.63% was higher than the control group 70.00%, After treatment, the nervous function defect scores at 7 day and 14 day in treatment group were lowed as compared with those in control (12.74±6.72 ) vs (24.71±8.51),P<0.01, had difference statistically significance,(13.85±7.93) vs (20.75±9.01), P<0.01, had difference statistically signiifcance. Conclusion Therapy of use low dose of urokinase combined with heparinin in the acute cerebral infarction is effect and safety.